GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline
Shots:
- GSK has reported an agreement with Chimagen Biosciences to acquire the CMG1A46. GSK aims to develop & commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as SLE & LN, to expand into other related autoimmune disorders.
- As per the agreement, GSK will pay $300M upfront for full global rights to CMG1A46. Chimagen may also receive up to $550M in milestone payments based on the successful development & commercialization. The agreement is subject to standard conditions, including required regulatory approvals under the Hart-Scott-Rodino Act in the US.
- CMG1A46 is a dual-targeted TCE that focuses on CD19&20. It is currently in a P-I study for leukemia and lymphoma in the US & China. GSK intends to launch a P-I study for lupus in 2025.
Ref: GSK | Image: GSK & Chimagen
Related News:- GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
